• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 4, 2022
Distillery Therapeutics

Inhibiting homotrimeric COL1 for pancreatic cancer

BioCentury | Feb 26, 2021
Distillery Therapeutics

Blocking COL1 for multiple sclerosis

DISEASE CATEGORY: Autoimmune disease
INDICATION: Multiple sclerosis (MS) Inhibiting fibrosis marker COL1 could treat MS. In an experimental autoimmune encephalomyelitis (EAE) mouse model of MS,
BioCentury | Apr 30, 2019
Distillery Therapeutics

BMP2/BMP6/activin A-based chimera for bone repair

BioCentury | Oct 25, 2018
Distillery Therapeutics

Pulmonary

BioCentury | Jun 14, 2017
Distillery Techniques

Imaging

BioCentury | Mar 24, 2017
Clinical News

HT-100 regulatory update

BioCentury | Mar 22, 2017
Clinical News

Akashi restarting development of DMD candidate

BioCentury | Oct 13, 2016
Product R&D

Elastic bones

A 3-D printable scaffold for bone repair
Items per page:
1 - 10 of 31